AUTHOR AND EDITOR INFORMATION

Section 1 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

INTRODUCTION

Section 2 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Background

In 1866, Down described clinical characteristics of the syndrome that now bears his name. In 1959, Lejeune and Jacobs et al independently determined that trisomy 21 is the cause.^{1, 2} Down syndrome is by far the most common and best known chromosomal disorder in humans. Mental retardation, dysmorphic facial features, and other distinctive phenotypic traits characterize the syndrome.

Pathophysiology

The extra chromosome 21 affects almost every organ system and results in a wide spectrum of phenotypic consequences. These include life-threatening complications, clinically significant alteration of life course (eg, mental retardation), and dysmorphic physical features. Down syndrome decreases prenatal viability and increases prenatal and postnatal morbidity. Affected children have delayed physical growth, maturation, bone development, and dental eruption.

The extra copy of the proximal part of 21q22.3 appears to result in the typical physical phenotype: mental retardation, characteristic facial features, hand anomalies, and congenital heart defects. Molecular analysis reveals that the 21q22.1-q22.3 region, or Down syndrome critical region (DSCR), appears to contain the gene or genes responsible for the congenital heart disease observed in Down syndrome. A new gene, DSCR1, identified in region 21q22.1-q22.2, is highly expressed in the brain and the heart and is a candidate for involvement in the pathogenesis of Down syndrome, particularly, in the mental retardation and/or cardiac defects.

Abnormal physiologic functioning affects thyroid metabolism and intestinal malabsorption. Frequent infections are presumably due to impaired immune responses, and the incidence of autoimmunity, including hypothyroidism and rare Hashimoto thyroiditis, is increased.

Patients with Down syndrome have decreased buffering of physiologic reactions, resulting in hypersensitivity to pilocarpine and abnormal responses on sensory-evoked electroencephalographic tracings. Children with leukemic Down syndrome also have hyperreactivity to methotrexate. Decreased buffering of metabolic processes results in a predisposition to hyperuricemia and increased insulin resistance. Diabetes mellitus develops in many affected patients. Premature senescence causes cataracts and Alzheimer disease. Leukemoid reactions of infancy and an increased risk of acute leukemia indicate bone-marrow dysfunction.

Children with Down syndrome are predisposed to developing leukemia, particularly transient myeloproliferative disorder and acute megakaryocytic leukemia. Nearly all children with Down syndrome who develop these types of leukemia have mutations in the hematopoietic transcription factor gene, GATA1. Leukemia in children with Down syndrome requires at least 3 cooperating events: trisomy 21, a GATA1 mutation, and a third undefined genetic alteration.

Frequency

United States

The frequency is 1 case in 800 live births. Each year, approximately 6000 children are born with Down syndrome.

Mortality/Morbidity

• Approximately 75% of concepti with trisomy 21 die in embryonic or fetal life. Approximately 85% of infants survive to age 1 year, and 50% can be expected to live longer than age 50 years. Congenital heart disease is the most important factor that determines survival. In addition, esophageal atresia with or without transesophageal (TE) fistula, Hirschsprung disease, duodenal atresia, and leukemia contribute to mortality. The high mortality rate later in life may be the result of premature aging.
• Individuals with Down syndrome have a greatly increased morbidity rate, primarily because of infections involving impaired immune response. Large tonsils and adenoids, lingual tonsils, choanal stenosis, or glossoptosis can obstruct the upper airway. Airway obstruction can cause serous otitis media, alveolar hypoventilation, arterial hypoxemia, cerebral hypoxia, and pulmonary arterial hypertension with resulting cor pulmonale and heart failure.
• A delay in recognizing atlantoaxial and atlanto-occipital instability may result in irreversible spinal-cord damage. Visual and hearing impairments in addition to mental retardation may further limit the child's overall function and may prevent him or her from participating in important learning processes and developing appropriate language and interpersonal skills. Unrecognized thyroid dysfunction may further compromise CNS function.

Race

No racial predilection is known.

Sex

The male-to-female ratio is increased (approximately 1.15:1) in newborns with Down syndrome. This effect is restricted to free trisomy 21.

Age

• Down syndrome can be diagnosed prenatally with amniocentesis, percutaneous umbilical blood sampling (PUBS), chorionic villus sampling (CVS), and extraction of fetal cells from the maternal circulation.
• Shortly after birth, Down syndrome is diagnosed by recognizing dysmorphic features and the distinctive phenotype.

CLINICAL

Section 3 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

History

When recording the history from the parents of a child with Down syndrome, the clinician should include the following:³

• Parental concern about hearing, vision, developmental delay, respiratory infections, and other problems
• Feeding history to ensure adequate caloric intake
• Prenatal diagnosis of Down syndrome
• Vomiting secondary to GI tract blockage by duodenal web or atresia
• Absence of stools secondary to Hirschsprung disease
• Delay in cognitive abilities, motor development, language development (specifically expressive skills), and social competence
• Arrhythmia, fainting episodes, palpitations, or chest pain secondary to heart lesion
• Symptoms of sleep apnea, including snoring, restlessness during sleep, difficulty awaking, daytime somnolence, behavioral changes, and school problems
• Symptoms of atlantoaxial instability
• • About 13-14% of patients have radiographic evidence of atlantoaxial instability but no symptoms.
  • Only 1-2% of patients have symptoms that require treatment.
  • Symptoms include easy fatigability, neck pain, limited neck mobility or head tilt, torticollis, difficulty walking, change in gait pattern, loss of motor skills, incoordination, clumsiness, sensory deficits, spasticity, hyperreflexia, clonus, extensor-plantar reflex, loss of upper-body strength, abnormal neurologic reflexes, change in bowel and bladder function, increased muscle tone in the legs, and changes in sensation in the hands and feet.
  • These symptoms often remain relatively stable for months or years.
  • In rare cases, the symptoms progress to paraplegia, hemiplegia, quadriplegia, or death.

Physical

• Growth: Short stature and obesity occurs during adolescence.
• CNS: Moderate-to-severe mental retardation occurs, with an intelligence quotient (IQ) of 20-85 (mean, approximately 50). Hypotonia improves with age. Articulatory problems are present. Sleep apnea occurs when inspiratory airflow from the upper airway to the lungs is impeded for 10 seconds or longer; it often results in hypoxemia or hypercarbia.
• Behavior: Natural spontaneity, genuine warmth, cheerful, gentleness, patience, and tolerance are characteristics. A few patients exhibit anxiety and stubbornness.
• Seizure disorder (5-10%): Infantile spasms are the most common seizures observed in infancy, whereas tonic-clonic seizures are most common in older patients.
• Premature aging: Decreased skin tone, early graying or loss of hair, hypogonadism, cataracts, hearing loss, age-related increase in hypothyroidism, seizures, neoplasms, degenerative vascular disease, loss of adaptive abilities, and increased risk of senile dementia of Alzheimer type are observed.
• Skull: Brachycephaly, microcephaly, a sloping forehead, a flat occiput, large fontanels with late closure, a patent metopic suture, absent frontal and sphenoid sinuses, and hypoplasia of the maxillary sinuses occur.
• Eyes: Up-slanting palpebral fissures, bilateral epicanthal folds, Brushfield spots (speckled iris), refractive errors (50%), strabismus (44%), nystagmus (20%), blepharitis (33%), conjunctivitis, tearing from stenotic nasolacrimal ducts, congenital cataracts (3%), pseudopapilledema, spasm nutans, acquired lens opacity (30-60%), and keratoconus in adults are observed.
• Nose: Hypoplastic nasal bone and flat nasal bridge are typical characteristics.
• Mouth and teeth: An open mouth with a tendency of tongue protrusion, a fissured and furrowed tongue, mouth breathing with drooling, a chapped lower lip, angular cheilitis, partial anodontia (50%), tooth agenesis, malformed teeth, delayed tooth eruption, microdontia (35-50%) in both the primary and secondary dentition, hypoplastic and hypocalcified teeth, malocclusion, taurodontism (0.54-5.6%), and increased periodontal destruction are noted.
• Ears: The ears are small with an overfolded helix. Chronic otitis media and hearing loss are common. About 66-89% of children have a hearing loss of greater than 15-20 dB in at least 1 ear, as assessed by means of the auditory brainstem response (ABR).
• Neck: Atlantoaxial instability (14%) can result from laxity of transverse ligaments that ordinarily hold the odontoid process close to the anterior arch of the atlas. Laxity can cause backward displacement of the odontoid process, leading to spinal cord compression in about 2% of children with Down syndrome.
• Chest: The internipple distance is decreased.
• Congenital heart defects: Congenital heart defects are common (40-50%); they are frequently observed in patients with Down syndrome who are hospitalized (62%), and they are a common cause of death in this aneuploidy in the first 2 years of life. The most common congenital heart defects are endocardial cushion defect (43%), ventricular septal defect (32%), secundum atrial septal defect (10%), tetralogy of Fallot (6%), and isolated patent ductus arteriosus (4%). About 30% of patients have several cardiac defects. The most common lesions are patent ductus arteriosus (16%) and pulmonic stenosis (9%). About 70% of all endocardial cushion defects are associated with Down syndrome.
• Abdomen: Diastasis recti and umbilical hernia occur.
• GI system (12%): Duodenal atresia or stenosis, Hirschsprung disease (<1%), TE fistula, Meckel diverticulum, imperforate anus, and omphalocele are observed. The prevalence rate of celiac disease in individuals with Down syndrome is reportedly 5-15% in different European and US studies. Celiac disease occurs in genetically susceptible individuals, specifically those who have the HLA heterodimers DQ2 (observed in 86-100% of individuals with celiac disease) and DQ8. These are strong linkages with high sensitivity and poor specificity.
• Genitourinary tract: Renal malformations, hypospadias, micropenis, and cryptorchidism occur.
• Skeleton: Short and broad hands, clinodactyly of the fifth fingers with a single flexion crease (20%), hyperextensible finger joints, increased space between the great toe and the second toe, and acquired hip dislocation (6%) are typical presentations.
• Endocrine system: Hypothyroidism (16-20% of young patients), diabetes, and decreased fertility occur. Thyroid disorders, such as congenital hypothyroidism, primary hypothyroidism, autoimmune thyroiditis, and compensated hypothyroidism or hyperthyrotropinemia, have been reported to have a prevalence rate of 3-54% in individuals with Down syndrome and increase in frequency with increasing age.
• Hematologic system
• • The relative risk of acute leukemia in the first 5 years of life is 56 times that of individuals without Down syndrome. Approximately one in 150 patients develops leukemia. Neonatal leukemoid reactions (ie, pseudoleukemia) are common, and distinguishing this from true leukemia frequently poses a diagnostic challenge.
  • Transient myeloproliferative disorder (TMD) associated with pancytopenia, hepatosplenomegaly, and circulating immature WBCs, is found almost exclusively in infants who have Down syndrome, with an incidence rate of approximately 10%. TMD spontaneously regresses within the first 3 months of life. However, in some children, it can be life threatening. Despite the high rate of spontaneous regression, TMD can be a preleukemic disorder in 20-30% of children with Down syndrome.
  • Acute myeloid leukemia (AML) is as common in these individuals as acute lymphoid leukemia (ALL). Acute megakaryocytic leukemia (AMKL) is the most common form of AML in affected children and is uncommon in children who do not have Down syndrome.
  • Although the risk for leukemia is higher in individuals with Down syndrome, these patients have a lower risk of developing solid tumors, with the exception of germ cell tumors and, perhaps, retinoblastomas and lymphomas.
  • The patient's risk of carrying hepatitis B is increased if previously institutionalized.
• Immunodeficiency: Patients have about a 12-fold increased risk of infectious diseases, especially pneumonia, because of impaired cellular immunity.
• Skin: Xerosis, localized hyperkeratotic lesions, elastosis serpiginosa, alopecia areata (<10%), vitiligo, folliculitis, abscess formation, and recurrent skin infections are observed.
• Dermatoglyphics: Distal axial triradius in the palms, transverse palmar creases, a single flexion crease in the fifth finger, ulnar loops (often 10), a pattern in hypothenar, and interdigital III regions are observed.
• Neurobehavioral disorders: Most children with Down syndrome do not have a coexisting psychiatric or behavioral disorder. The available estimates of psychiatric comorbidity range from 18-38%. The disorders include attention deficit hyperactivity disorder, oppositional defiant disorder, nonspecific disruptive disorder, autism spectrum disorders, and stereotypical movement disorder in prepubertal children with Down syndrome and depressive illness, obsessive-compulsive disorder, and psychoticlike disorder in adolescents and adults with Down syndrome.

Causes

• The cause of Down syndrome is full trisomy 21 in 94% of patients. Mosaicism (2.4%) and translocations (3.3%) account for the rest. Approximately 75% of the unbalanced translocations are de novo, and approximately 25% result from familial translocation.
• The most common error is maternal nondisjunction in the first meiotic division, with meiosis I errors occurring 3 times as frequently as meiosis II errors. The remaining cases are paternal in origin, and meiosis II errors predominate.
• Most mosaic cases result from a trisomic zygote with mitotic loss of 1 chromosome.
• Advanced maternal age remains the only well-documented risk factor for maternal meiotic nondisjunction. However, understanding of the basic mechanism behind the maternal age effect is lacking.
• • With a maternal age of 35 years, the risk is 1 in 385.
  • With a maternal age of 40 years, the risk is 1 in 106.
  • With a maternal age of 45 years, the risk is 1 in 30.
• Cytogenetic and molecular studies suggest that dup21(q22.1-22.2) is sufficient to cause Down syndrome. The DSCR contains genes coding for enzymes, such as superoxide dismutase 1 (SOD1), cystathionine beta-synthase (CBS), glycinamide ribonucleotide synthase-aminoimidazole ribonucleotide synthase-glycinamide formyl transferase (GARS-AIRS-GART).

DIFFERENTIALS

Section 4 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Other Problems to be Considered

49,XXXXY chromosome
Other high-order multiple X chromosomes
Zellweger syndrome
Other peroxisomal disorders

WORKUP

Section 5 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Lab Studies

• Cytogenetic studies: The clinical diagnosis should be confirmed with cytogenetic studies.
• • Karyotyping is essential to determine the risk of recurrence.
  • In translocation Down syndrome, karyotyping of the parents and other relatives is required for proper genetic counseling.
• Interphase fluorescence in situ hybridization (FISH): FISH may be used for rapid diagnosis. It can be successful in both prenatal diagnosis and diagnosis in the neonatal period.
• Thyroid function tests: Thyroid-stimulating hormone (TSH) and thyroxine (T4) levels should be obtained at birth and annually thereafter.
• Measurement of immunoglobulin G (IgG): This test is used to identify a deficiency of subclasses 2 and 4.
• • Decreased levels of IgG subclass 4 is significantly correlated with bacterial infections.
  • These deficits in cellular immunity have also been documented in individuals with gingivitis and periodontal disease.
• Papanicolaou test (Pap smear): Perform Pap smears every 1-3 years in sexually active women starting at the age of first intercourse.

Imaging Studies

• Skeletal radiography
• • Craniofacial anomalies include brachycephalic microcephaly and hypoplastic facial bones and sinuses.
  • Cervical radiography (with lateral flexion and extension views) is required to measure the atlantodens distance and to rule out atlantoaxial instability at the age of 3 years. Radiography is also used before anesthesia is given if signs suggest spinal cord compression.
  • Reduced iliac and acetabular angles may be present in young infants.
  • Short hands with shortened digits and clinodactyly due to hypoplastic middle phalanx of the fifth finger may be present.
• Echocardiography: This test should be performed on all infants with Down syndrome to identify congenital heart disease, regardless of findings on physical examination.
• Mammography: Obtain yearly mammograms in women older than 50 years.

Other Tests

• ABR testing: Also known as brainstem auditory evoked response (BAER), the ABR demonstrates hearing loss. Evaluation of the ABR in 47 nonselected children with Down syndrome aged 2 months to 3.5 years indicated some hearing loss in 66% (28% unilateral, 38% bilateral).
• Speech evaluation
• Ophthalmic examination: Pediatric ophthalmic examination should be performed for vision screening and for detecting ophthalmologic disorders.
• Developmental chart: A developmental chart for noninstitutionalized children based on a modified Denver Developmental Screening Test is available for assessing developmental milestones.
• Growth charts: Growth charts are available for children with Down syndrome.
• • An increased incidence of celiac disease has been reported in Down syndrome.
  • Evaluation should be prompted by recognition of signs and symptoms, such as growth failure, abdominal pain, and loose stools.
• Dental care: Rigorous dental hygiene and dental evaluation, beginning after tooth eruption

TREATMENT

Section 6 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Medical Care

Despite continued work, no notable medical treatments for mental retardation associated with Down syndrome have been forthcoming. However, the dramatic improvements in medical care described below have greatly improved the quality of life for patient and increased their life expectancy.

• Genetic counseling
• • Trisomy 21: If the couple has a child with trisomy 21, the risk of recurrence is about 1%. The risk does not appear to be increased in siblings of affected individuals.
  • Translocation Down syndrome: If the child has a translocation, a balanced translocation must be excluded in the parents.
  • Robertsonian translocation: In cases of de novo Robertsonian translocation, the risk of Down syndrome in a subsequent pregnancy is an estimated 2-3%. If either parent has a translocation, start additional family studies and counseling. A parent with a balanced Robertsonian translocation is phenotypically normal but has an increased risk of having a chromosomally unbalanced offspring. The theoretic recurrence risk for a Robertsonian carrier parent to have a liveborn offspring with Down syndrome is 1 in 3. However, only 10-15% of the progeny of carrier mothers and only 2-3% of the progeny of carrier fathers have Down syndrome. The reason for this difference is not clear. In a carrier parent with a 21q21q translocation or isochromosome, the recurrence risk is 100%.
  • Mosaic Down syndrome: Most patients with mosaic Down syndrome were once trisomy 21 zygotes. The phenotype varies and possibly reflects the variable proportion of trisomy 21 cells in the embryo during early development. In rare instances, low-level mosaicism in germinal tissue of a parent is postulated to be the cause of more than 1 trisomic child in the family.
  • Reproduction: Affected individuals rarely reproduce. About 15-30% of females with trisomy 21 are fertile, and they have a 50% risk of having an affected child. The literature contains reports of 4 pregnancies fathered by 3 male patients with Down syndrome. Infertility in males has been attributed to defective spermatogenesis, but ignorance of the sexual act may be one of the contributing factors.
• Vaccination and medication
• • Usual immunizations and well childcare should be performed as the American Academy of Pediatrics recommends.
  • Thyroid hormone for hypothyroidism is needed to prevent intellectual deterioration and improve the individual's overall function, academic achievement, and vocational abilities.
  • Subacute bacterial endocarditis prophylaxis is needed in susceptible children with cardiac disease when they undergo dental work or other invasive procedures.
  • Digitalis and diuretics are usually required for cardiac management.
  • Prompt treatment of respiratory tract infections and otitis media is necessary.
  • Children with chronic cardiac and respiratory disease are candidates for pneumococcal and influenza vaccination.
  • Administer anticonvulsants for tonic-clonic seizures or for infantile spasms (treat with steroids).
  • Provide pharmacologic agents, psychotherapy, and/or behavior therapies for psychiatric disorders.
  • Treat skin disorders with weight reduction, proper hygiene, frequent baths, application of antibiotic ointment, or systemic antibiotic therapy.
  • Prevent dental caries and periodontal disease through appropriate dental hygiene, fluoride treatments, good dietary habits, and restorative care.
  • Early intervention programs are promising. Programs for infants aged 0-3 years are designed to comprehensively monitor and enrich their development by focusing on feeding, as well as gross and fine motor, language, personal, and social development. Early intervention techniques may improve the patient's social quotient. Overall, positive developmental changes are observed in children with Down syndrome, particularly in terms of their independence, community functioning, and quality of life.
  • Megadoses of vitamins and minerals supplemented with zinc and/or selenium were not beneficial in a number of well-controlled scientific studies.
  • Children with Down syndrome and leukemia are more sensitive to some chemotherapeutic agents (eg, methotrexate) than other children. Thus, they require careful monitoring for toxicity.
• Medical care and monitoring for the adolescent with Down syndrome
• • Perform annual audiologic evaluation.
  • Perform annual ophthalmologic evaluations for keratoconus or corneal opacities and/or cataracts.
  • Treat dermatologic issues, such as folliculitis, xerosis, atopic dermatitis, seborrheic dermatitis, fungal infections of skin and nails, vitiligo, and alopecia.
  • Prevent obesity by decreasing the patient's caloric intake and increasing activity (social and leisure).
  • Screen for celiac disease (symptoms such as constipation, diarrhea, bloating, poor growth, or weight loss) and treat the patient with a gluten-free diet.
  • Swallowing difficulties may persist through the adolescent years and must be addressed.
  • Antibiotic prophylaxis during dental and surgical procedures in the presence of mitral valve prolapse
  • Treatment options should include bone marrow transplantation if leukemia occurs.
  • Treat airway obstruction medically and surgically.
  • Special attention to perioperative modalities because of atlantoaxial instability and problems with the respiratory system.
  • Screen for hypothyroidism and diabetes mellitus.
  • Address concerns regarding menstrual hygiene, sexual abuse, pregnancy, and premenstrual syndrome.
  • Manage neurologic problems, including mental retardation, hypotonia, seizures, and strokes.
  • Continue speech and language therapy, with a focus on expressive language and intelligibility.
  • Evaluate and treat behavioral problems, such as disruptive behavior disorders, stereotypic behaviors, phobias, elimination difficulties, autism, eating problems, self-injurious behavior, and Tourette syndrome.
  • Evaluate and treat psychiatric disorders, such as depression, and self-talk.
  • Assist the patient's eventual medical transition and occupational issues.
  • During adolescence, an additional 2% of patients die from complications of congenital heart disease, infections, leukemia, and accidents. Continue subacute bacterial endocarditis prophylaxis in adolescents with cardiac defects.
  • Repeat cervical spine radiography as needed for Special Olympics participation.
  • Discuss issues related to transition to adulthood.
  • Emphasize the importance of a well-balanced diet and routine exercise.
  • Review plans for school placement and plans after high-school graduation and future vocational plans.
  • Discuss plans for alternative long-term living arrangements such as community living arrangements. Parents should update estate planning and custody arrangements.
  • Encourage social and recreational programs with friends.
  • Discuss sexuality and socialization and the need for and degree of supervision required. Review options for contraception if the teen is sexually active. Make recommendations for routine gynecologic care.
  • Monitor the family's need for supportive care or counseling, respite care, and behavior management techniques. Facilitate referrals for respite care and treatment of parental problems.
  • Facilitate transfer to adult health care.

Surgical Care

• Down syndrome alone does not adversely affect surgical outcomes in the absence of pulmonary hypertension.
• Timely surgery of cardiac anomalies, which are common during the first 6 months of life, may be necessary to prevent serious complications.
• Prompt surgical repair is necessary for GI anomalies, such as TE fistula, pyloric stenosis, duodenal atresia, annular pancreas, aganglionic megacolon, and imperforate anus.
• Adenotonsillectomy may be performed to manage obstructive sleep apnea.
• Surgical intervention may be necessary to reduce atlantoaxial subluxation and to stabilize the upper segment of the cervical spine if neurologic deficits are clinically significant.
• Anesthetic airway management may be needed.
• • Preoperative evaluation for anesthesia must include adequate evaluation of the airway and the patient's neurologic status.
  • Cervical radiography (with flexion and extension views) should be performed when any neurologic deficit suggests spinal-cord compression.
  • During laryngoscopy and intubation, the patient's head should be maintained in a neutral position, and hyperextension should be avoided.
  • Anticholinergics can be prescribed to control hypersecretion in the airways.
  • Other airway complications include subglottic stenosis and obstructive apnea, which may result from a relatively large tongue, enlarged adenoids, and midfacial hypoplasia.
• Congenital cataracts occur in about 3% of children and must be extracted soon after birth to allow light to reach the retina. Afterward, appropriate correction with glasses or contact lenses helps ensure adequate vision.

Consultations

• Clinical geneticist
• Developmental pediatrician
• Cardiologist
• Ophthalmologist
• Neurosurgeon
• Orthopedic specialist
• Psychiatrist
• Physical and occupational therapist
• Speech-language pathologist
• Audiologist

Diet

• No special diet is required, unless celiac disease is present. A balanced diet and regular exercise are needed to maintain appropriate weight.
• Feeding problems and failure to thrive usually improve after cardiac surgery.

Activity

• No restriction of activities is necessary. Advise the patient to exercise to maintain an appropriate weight.
• Patients with symptoms of arrhythmia, episodes of fainting, abnormal findings on ECG, and palpitations or chest pain should refrain from participating in sports and strenuous exercise.
• Children with C1-C2 subluxation should be allowed to compete in the Special Olympics unless they have symptoms of cervical-cord compression.

MEDICATION

Section 7 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Drug therapy is currently not a component of the standard of care for this syndrome.

FOLLOW-UP

Section 8 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Further Inpatient Care

• Manage cardiac defects medically or surgically.
• Regular screening is necessary for institutionalized older adults to diagnose early-onset dementia, epilepsy, hypothyroidism, and early loss of visual acuity and hearing.
• Cytogenetic studies are necessary to confirm the clinical diagnosis.

Further Outpatient Care

• Audiologic evaluation for hearing loss
• Apnea monitoring

In/Out Patient Meds

• Diuretics and digoxin should be used to manage congestive heart failure secondary to congenital heart defect.

Complications

• After adenotonsillectomy, patients have long periods of decreased oxygenation and slowed recovery times.
• Otitis media and upper respiratory tract infections are common.
• Feeding problems and poor weight gain may occur because of congenital heart disease.
• Congenital heart disease is the major cause of death.

Prognosis

• The overall outlook for individuals with Down syndrome has improved dramatically. Many adult patients are healthier, they are better integrated into society, and they have increased longevity than before. However, their life expectancy is still reduced.
• Congenital heart disease is the major cause for early mortality.
• Leukemia, thyroid diseases, autoimmune disorders, and susceptibility to infections related to an abnormal serum IgG subclass pattern are common.
• Many patients develop progressive Alzheimer-like dementia by the age of 40 years, and 75% of patients have signs and symptoms of Alzheimer disease.

Patient Education

• Career preparation should include acquisition of job skills, choice of job area, development of work-support behavior, and opportunities for job mobility. The goal of successful transition from school to the world of work is meaningful employment and optimal function in the least restrictive environment.
• Opportunities to participate in community life should be made available.
• Individuals should be encouraged to pursue daily living tasks with minimal or no assistance.
• Patients should participate in cultural, leisure, and recreational activities during the growing years.
• Patients may qualify for supplemental security income (SSI) depending on their family's income.
• Additional resources can be obtained from the following organizations:
• • The National Down Syndrome Society
    666 Broadway, 8th Floor
    New York, NY 10012-2317
    Phone: 212-460-9330 or 800-221-4602
    Fax: 212-979-2873
    E-mail: info@ndss.org
  • National Down Syndrome Congress
    1370 Center Drive, Suite 102
    Atlanta, GA 30338
    Phone: 770-604-9500 or 800-232-NDSC
    E-mail: info@ndscenter.org
  • National Association for Down Syndrome
    PO Box 206
    Wilmette, IL 60091
    Phone: 630-325-9112
  • International Resource Center for Down Syndrome, Cleveland, OH
  • The Arc
    The Arc of the United States
    1010 Wayne Avenue, Suite 650
    Silver Spring, MD 20910
    Phone: (301) 565-3842
  • The Down Syndrome WWW page
• For excellent patient education resources, visit eMedicine's Brain and Nervous System Center. Also, see eMedicine's patient education article Down Syndrome.

MISCELLANEOUS

Section 9 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Medical/Legal Pitfalls

• Failure to identify characteristic symptoms and signs of Down syndrome and to refer patient to a geneticist for evaluation and genetic counseling
• Failure to order chromosomal analysis when Down syndrome is clinically diagnosed
• Failure to offer prenatal screening to pregnant women
• Failure to offer prenatal diagnosis after a woman has an affected child
• Reliance on maternal serum triple-marker screening for prenatal diagnosis in a pregnancy at risk for Down syndrome (Amniocentesis and CVS are the criterion standard diagnostic tests for prenatal diagnosis in a pregnancy at increased risk.)

Special Concerns

• Awareness: Physicians and parents should be aware of the range of psychomotor potential so that early intervention, schooling, and community placement are provided.
• Prenatal screening
• • Advanced maternal age: The first prenatal diagnosis of Down syndrome was made in 1968, and screening women on the basis of advanced maternal age with amniocentesis was gradually introduced into medical practice.
  • Maternal serum biochemical markers: Low maternal serum alpha-fetoprotein (MSAFP) levels were associated with Down syndrome in 1983. Later, elevated human chorionic gonadotropin (hCG) and low unconjugated estriol (uE3) levels were found to be markers for Down syndrome. By 1988, use of the 3 biochemical markers, together with maternal age, had been accepted as a method of prenatal screening for Down syndrome in the general population.
  • • When ultrasonography is used to estimate gestational age, the detection rate is about 20% when only the MSAFP test is used, 59% when the double test (MSAFP and hCG) is used, and 69% when the triple test (MSAFP, hCG, uE3) is used. The false-positive rate is 5%. Other factors for adjustment are maternal age and weight, insulin-dependent diabetes mellitus, multiple pregnancies, racial background, previous pregnancy with Down syndrome, and first or repeat test in a pregnancy. A positive screening result only suggests an increased risk for Down syndrome, and definitive testing with amniocentesis with chromosomal analysis is indicated.
    • In a retrospective study of first-trimester screening for free beta-hCG and pregnancy-associated plasma protein A (PAPP-A), detection rates were as high as those associated with MSAFP, hCG, or uE3 testing in the second trimester. Prospective studies are needed to further assess first-trimester screening.
  • Prenatal ultrasonography
  • • Ultrasonography soft markers observed in the second trimester for Down syndrome include absent or hypoplastic nasal bone, thickened nuchal fold, echogenic bowel, shortened long bones, and pyelectasis.
    • Absent or hypoplastic nasal bone is observed in 43-62% of trisomy 21 fetuses compared with 0.5-1.2% observed in normal fetuses.
    • A thickened nuchal fold has been associated with a greatly increased risk of trisomy 21 and may be an early feature of fetal hydrops or cystic hygroma.
    • Echogenic bowel has been observed in approximately 15% of fetuses with trisomy 21 compared with 0.6% observed in normal fetuses. About 35% of fetuses with true echogenic bowel have some underlying pathology, such as first trimester bleeding, fetal infections, and cystic fibrosis due to meconium ileus.
    • Shortened long bones (humerus and femur) have been associated with an increased risk of chromosomal abnormalities. The humerus is a more reliable discriminator for Down syndrome than the femur. The humerus appears to be the next most important marker after nasal bone and nuchal fold. The other possible causes include skeletal dysplasia, especially if the long bones are severely shortened or abnormal in appearance (eg, bowing fractures or reduced mineralization).
    • Pyelectasis has been observed in approximately 17% of fetuses with trisomy 21. Approximately 1 in every 300 fetuses with isolated pyelectasis has aneuploidy. Pyelectasis has been associated with an increased risk of hydronephrosis and postnatal urinary reflux.
    • Other ultrasonography abnormalities include cystic hygroma, duodenal atresia or stenosis (double-bubble sign), cardiac defects (endocardial cushion defect with atrial and ventricular septal defects and abnormal mitral and tricuspid valves), and intracardiac echogenic focus.
    • Ultrasonography should not be relied on as the primary method of diagnosing Down syndrome, and the diagnosis can be missed in affected families.
  • Extraction of fetal cells from the maternal circulation: After fetal nucleated RBCs are sorted by using different cell transferrin and glycophorin-A receptors on the cell surface, interphase FISH can be used to determine the chromosomal constitution. Chromosome-specific probes available for X, Y, 13, 18, and 21 permit diagnosis. The FISH finding should be confirmed by using standard cytogenetic techniques.
• Prenatal diagnosis
• • Amniocentesis, routinely performed at 14-16 weeks' gestation, remains the criterion standard of invasive diagnostic tests. Testing for chromosomal disorders is 99.5% accurate. Rare cases of mosaicism are missed, and results can be inaccurate if maternal-cell contamination occurs. The procedure is associated with a small risk of pregnancy loss (1:200-300).
  • CVS is performed at 10-13 weeks' gestation. Testing earlier than this is thought to be associated with a 1 in 300-1000 risk of fetal transverse limb deficiency, a small risk of maternal cell contamination, and a 0.5-1% risk of a fetal loss after the procedure. The accuracy (96-98%) is less than that of midtrimester amniocentesis because of confined placental mosaicism and maternal-cell contamination.
  • PUBS is approximately 95% successful in obtaining a blood sample for cytogenetic testing. The pregnancy-loss rate is 3.25% for PUBS done for chromosomal indications versus 1.25% and 2.75% for PUBS done for nonchromosomal indications. The indication for the procedure greatly increases the risk of procedure-related pregnancy loss.
  • The availability of in vitro fertilization has allowed for preimplantation diagnosis of single-gene disorders, for sex selection for X-linked disorders, and for identifying chromosomal aneuploidies. After a biopsy sample is obtained from the first polar body, the blastocyst, or the 6- to 8-cell embryo, FISH can then be used to diagnose fetal aneuploidy. However, standard cytogenetic confirmation is not possible for the preimplantation diagnosis.

MULTIMEDIA

Section 10 of 11  

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

Media file 1:  Infant with Down syndrome. Note up-slanting palpebral fissures, bilateral epicanthal folds, flat nasal bridge, open mouth with tendency of tongue protrusion, and small ear with overfolded helix.
	View Full Size Image
Media type:  Photo

Media file 2:  Child with Down syndrome. Note up-slanting palpebral fissures, bilateral epicanthal folds, a small nose with flat nasal bridge, open mouth with tendency for tongue protrusion, and small ears with overfolded helix.
	View Full Size Image
Media type:  Photo

Media file 3:  G-banded karyotype showing trisomy 21 (47,XY,+21).
	View Full Size Image
Media type:  Photo

Media file 4:  G-banded karyotype showing trisomy 21 of isochromosome arm 21q type [46,XY,i(21)(q10)].
	View Full Size Image
Media type:  Photo

Media file 5:  Hand of an infant with Down syndrome. Note the transverse palmar crease and clinodactyly of the 5th finger.
	View Full Size Image
Media type:  Photo

Media file 6:  Ear of an infant with Down syndrome. Note the characteristic small ear with overfolded helix.
	View Full Size Image
Media type:  Photo

REFERENCES

Section 11 of 11

• Authors and Editors
• Introduction
• Clinical
• Differentials
• Workup
• Treatment
• Medication
• Follow-up
• Miscellaneous
• Multimedia
• References

1. Lejeune J. Le mongolisme. Premier example d'aberration autosomique humaine. Ann Genet. 1959;1:41-9.
2. Jacobs PA, Baikie AG, Court Brown WM, Strong JA. The somatic chromosomes in mongolism. Lancet. Apr 4 1959;1(7075):710. [Medline].
3. Cohen WI, ed. Health care guidelines for individuals with Down syndrome (Down syndrome preventative medical check list). Down Syndrome Q. 1996;1(2):1-10. [Full Text].
4. AAP. Health supervision for children with Down syndrome: American Academy of Pediatrics Committee on Genetics. Pediatrics. May 1994;93(5):855-9. [Medline].
5. Allshouse MJ. Trisomy 21 and the pediatric surgeon. Curr Opin Pediatr. Jun 2006;18(3):298-304. [Medline].
6. Bahado-Singh RO, Choi SJ, Cheng CC. First- and midtrimester Down syndrome screening and detection. Clin Perinatol. Dec 2004;31(4):677-94, v. [Medline].
7. Bethune M. Literature review and suggested protocol for managing ultrasound soft markers for Down syndrome: thickened nuchal fold, echogenic bowel, shortened femur, shortened humerus, pyelectasis and absent or hypoplastic nasal bone. Australas Radiol. Jun 2007;51(3):218-25. [Medline].
8. Capone G, Goyal P, Ares W, Lannigan EY. Neurobehavioral disorders in children, adolescents, and young adults with Down syndrome. Am J Med Genet Part C (Seminar in Medical Genet). Aug 15 2006;142(3):158-72. [Medline].
9. Carey JC. Health supervision and anticipatory guidance for children with genetic disorders (including specific recommendations for trisomy 21, trisomy 18, and neurofibromatosis I). Pediatr Clin North Am. Feb 1992;39(1):25-53. [Medline].
10. Chen H, Woolley PV Jr. A developmental assessment chart for non-institutionalized Down syndrome children. Growth. Jun 1978;42(2):157-65. [Medline].
11. Cohen WI. Current dilemmas in Down syndrome clinical care: Celiac disease, thyroid disorders, and atlanto-axial instability. Am J Med Genet Part C (Seminar in Medical Genet). Aug 15 2006;142(3):141-8. [Medline].
12. Cronk C, Crocker AC, Pueschel SM, et al. Growth charts for children with Down syndrome: 1 month to 18 years of age. Pediatrics. Jan 1988;81(1):102-10. [Medline].
13. Dent KM, Carey JC. Breaking difficult news in a newborn setting: Down syndrome as a paradigm. Am J Med Genet C Semin Med Genet. Aug 15 2006;142(3):173-9. [Medline].
14. Dixon N, Kishnani PS, Zimmerman S. Clinical manifestations of hematologic and oncologic disorders in patients with Down syndrome. Am J Med Genet C Semin Med Genet. Aug 15 2006;142(3):149-57. [Medline].
15. Dutta S, Nandagopal K, Gangopadhyay PK, Mukhopadhyay K. Molecular aspects of down syndrome. Indian Pediatr. Apr 2005;42(4):339-44. [Medline].
16. Epstein CJ. The consequences of chromosome imbalance. Am J Med Genet Suppl. 1990;7:31-7. [Medline].
17. Ferencz C, Neill CA, Boughman JA, et al. Congenital cardiovascular malformations associated with chromosome abnormalities: an epidemiologic study. J Pediatr. Jan 1989;114(1):79-86. [Medline].
18. Findlay I, Toth T, Matthews P, et al. Rapid trisomy diagnosis (21, 18, and 13) using fluorescent PCR and short tandem repeats: applications for prenatal diagnosis and preimplantation genetic diagnosis. J Assist Reprod Genet. May 1998;15(5):266-75. [Medline].
19. Fuentes JJ, Pritchard MA, Planas AM, et al. A new human gene from the Down syndrome critical region encodes a proline-rich protein highly expressed in fetal brain and heart. Hum Mol Genet. Oct 1995;4(10):1935-44. [Medline].
20. Greenwood RD, Nadas AS. The clinical course of cardiac disease in Down's syndrome. Pediatrics. Dec 1976;58(6):893-7. [Medline].
21. Hata T, Todd MM. Cervical spine considerations when anesthetizing patients with Down syndrome. Anesthesiology. Mar 2005;102(3):680-5. [Medline].
22. Heller JH, Spiridigliozzi GA, Crissman BG, Sullivan-Saarela JA, Li JS, Kishnani PS. Clinical trials in children with Down syndrome: issues from a cognitive research perspective. Am J Med Genet C Semin Med Genet. Aug 15 2006;142(3):187-95. [Medline].
23. Hines S, Bennett F. Effectiveness of early intervention for children with Down syndrome. Ment Retard Dev Disabil Res Rev. 1996;2:96-101.
24. Huether CA, Martin RL, Stoppelman SM, et al. Sex ratios in fetuses and liveborn infants with autosomal aneuploidy. Am J Med Genet. Jun 14 1996;63(3):492-500. [Medline].
25. Knox GE, ten Bensel RW. Gastrointestinal malformations in Down's Syndrome. Minn Med. Jun 1972;55(6):542-4. [Medline].
26. Korenberg JR, Bradley C, Disteche CM. Down syndrome: molecular mapping of the congenital heart disease and duodenal stenosis. Am J Hum Genet. Feb 1992;50(2):294-302. [Medline].
27. Krantz DA, Larsen JW, Buchanan PD, Macri JN. First-trimester Down syndrome screening: free beta-human chorionic gonadotropin and pregnancy-associated plasma protein A. Am J Obstet Gynecol. Feb 1996;174(2):612-6. [Medline].
28. Lin YC. Cervical spine disease and Down syndrome in pediatric anesthesia. Anesth Clin North Am. 1998;16:911-23.
29. Madan V, Williams J, Lear JT. Dermatological manifestations of Down's syndrome. Clin Exp Dermatol. Sep 2006;31(5):623-9. [Medline].
30. Marino B. Congenital heart disease in patients with Down's syndrome: anatomic and genetic aspects. Biomed Pharmacother. 1993;47(5):197-200. [Medline].
31. Nicolaidis P, Petersen MB. Origin and mechanisms of non-disjunction in human autosomal trisomies. Hum Reprod. Feb 1998;13(2):313-9. [Medline]. [Full Text].
32. Opitz JM, Gilbert-Barness EF. Reflections on the pathogenesis of Down syndrome. Am J Med Genet Suppl. 1990;7:38-51. [Medline].
33. Pangalos C, Avramopoulos D, Blouin JL, et al. Understanding the mechanism(s) of mosaic trisomy 21 by using DNA polymorphism analysis [published erratum appears in Am J Hum Genet 1994 Jul;55(1):217]. Am J Hum Genet. Mar 1994;54(3):473-81. [Medline].
34. Park SC, Mathews RA, Zuberbuhler JR, et al. Down syndrome with congenital heart malformation. Am J Dis Child. Jan 1977;131(1):29-33. [Medline].
35. Pradhan M, Dalai A, Khan F, Agrawal S. Fertility in men with Down syndrome: a case report. Fertility Sterility. 2006;86:1765e1-13.
36. Pueschel SM. Clinical aspects of Down syndrome from infancy to adulthood. Am J Med Genet Suppl. 1990;7:52-6. [Medline].
37. Pueschel SM. Young people with Down syndrome: transition from childhood to adulthood. Ment Retard Dev Disab Res Rev. 1996;2:90-5.
38. Pueschel SM, Rynders JE. Down Syndrome: Advances in Biomedicine and the Behavioral Sciences. Cambridge, MA: Ware; 1982.
39. Roberts JE, Price J, Malkin C. Language and communication development in Down syndrome. Ment Retard Dev Disability Res Rev. 2007;13:26-35.
40. Roizen NJ. Down syndrome and associated medical disorders. Ment Retard Dev Disab Res Rev. 1996;2:85-9.
41. Roizen NJ. Medical care and monitoring for the adolescent with Down syndrome. Adolesc Med. Jun 2002;13(2):345-58, vii. [Medline].
42. Roizen NJ, Wolters C, Nicol T, Blondis TA. Hearing loss in children with Down syndrome. J Pediatr. Jul 1993;123(1):S9-12. [Medline].
43. Rose NC. Pregnancy screening and prenatal diagnosis of fetal Down syndrome. Ment Retard Dev Disab Res Rev. 1996;2:80-4.
44. Rowe RD, Uchida IA. Cardiac malformation in mongolism: a prospective study of 184 mongoloid children. Am J Med. Nov 1961;31:726-35. [Medline].
45. Shott SR. Down syndrome: common otolaryngologic manifestations. Am J Med Genet C Semin Med Genet. Aug 15 2006;142(3):131-40. [Medline].
46. Skotko BG, Levine SP. What the other children are thinking: brothers and sisters of persons with Down syndrome. Am J Med Genet C Semin Med Genet. Aug 15 2006;142(3):180-6. [Medline].
47. US Preventive Services Task Force. Screening for Down syndrome. In: Guide to Clinical Preventive Services. 2^nd ed. Baltimore, MD: Lippincott, Williams & Wilkins; 1996:449-65.
48. Van Buggenhout GJ, Trommelen JC, Schoenmaker A, et al. Down syndrome in a population of elderly mentally retarded patients: genetic-diagnostic survey and implications for medical care. Am J Med Genet. Aug 6 1999;85(4):376-84. [Medline].
49. Van Cleve SN, Cannon S, Cohen WI. Part II: Clinical Practice Guidelines for adolescents and young adults with Down Syndrome: 12 to 21 Years. J Pediatr Health Care. May-Jun 2006;20(3):198-205. [Medline].
50. Vyas P, Crispino JD. Molecular insights into Down syndrome-associated leukemia. Curr Opin Pediatr. Feb 2007;19(1):9-14. [Medline].
51. Wald NJ, Kennard A, Hackshaw A, McGuire A. Antenatal screening for Down's syndrome. J Med Screen. 1997;4(4):181-246. [Medline].
52. Wells GL, Barker SE, Finley SC, Colvin EV, Finley WH. Congenital heart disease in infants with Down's syndrome. South Med J. Jul 1994;87(7):724-7. [Medline].
53. Zeller B, Gustafsson G, Forestier E, et al. Acute leukaemia in children with Down syndrome: a population-based Nordic study. Br J Haematol. Mar 2005;128(6):797-804. [Medline].
54. Zigman W, Silverman W, Wisniewski HM. Aging and Alzheimer's disease in Down syndrome: clinical and pathological changes. Ment Retard Dev Disab Res Rev. 1996;2:73-9.

Article Last Updated: Aug 13, 2007